Continue licensing Harbour Antibodies' transgenic mice platforms. Harbour Antibodies will remain a subsidiary of Harbour BioMed and will continue to manage the licensing operations.
Expand the range of partnerships around Harbour's platforms and innovative drug development programs by capitalizing on the Harbour BioMed management team's extensive worldwide drug discovery and development expertise.
- Co-development of discovery programs for global market.
- In-license of clinical-ready and clinical stage assets for China market.